Dermatomyositis: Dermatological Features

  • Liam Zakko
  • Justin Finch
  • Marti J. Rothe
  • Jane M. Grant-Kels


Clinical signs and features include:

Bimodal incidence pattern—childhood and then age 50–70s; four to ten new cases per million; more common in women

Associated with internal malignancy in about 25 % of cases, especially adenocarcinoma of ovary, lung, and gastrointestinal tract in Western countries and nasopharyngeal carcinomas in South East Asia, Southern China, and North Africa; the diagnosis of dermatomyositis may be made prior to, concurrently, or after the diagnosis of malignancy; age-appropriate malignancy surveillance is recommended

Muscle symptoms: symmetric proximal muscle and truncal weakness that develops relatively slowly over the course of weeks to months, occasionally associated with myalgias and muscle tenderness early in the disease course. It is atypical for muscle disease to precede skin manifestations.


Interstitial Lung Disease Muscle Symptom Topical Calcineurin Inhibitor Internal Malignancy Amyopathic Dermatomyositis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Khan S, Christopher-Stine L. Polymyositis, dermatomyositis, and autoimmune necrotizing myopathy: clinical features. Rheum Dis Clin North Am. 2011;37:143–58.PubMedCrossRefGoogle Scholar
  2. 2.
    Ramos-E-Silva M, Carvalho JC, Carneiro SC. Cutaneous paraneoplasia. Clin Dermatol. 2011;29:541–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Zahr ZA, Baer AN. Malignancy in myositis. Curr Rheumatol Rep. 2011;13:208–15.PubMedCrossRefGoogle Scholar
  4. 4.
    Nagaraju K, Lundberg IE. Polymyositis and dermatomyositis: pathophysiology. Rheum Dis Clin North Am. 2011;37:159–71.PubMedCrossRefGoogle Scholar
  5. 5.
    Marie I, Mouthon L. Therapy of polymyositis and dermatomyositis. Autoimmun Rev. 2011;11:6–13.PubMedCrossRefGoogle Scholar
  6. 6.
    Rowin J, Amato AA, Deisher N, et al. Mycophenolate mofetil in dermatomyositis: is it safe? Neurology. 2006;66:1245–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Dawkins MA, Jorizzo JL, Walker FO, et al. Dermatomyositis. A dermatology-based case series. J Am Acad Dermatol. 1998;38:397–404.PubMedCrossRefGoogle Scholar
  8. 8.
    Kim JE, Jeong MG, Lee HE, et al. Successful treatment of cutaneous lesions of dermatomyositis with topical pimecrolimus. Ann Dermatol. 2011;23:348–51.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Liam Zakko
    • 1
  • Justin Finch
    • 2
  • Marti J. Rothe
    • 2
  • Jane M. Grant-Kels
    • 2
  1. 1.Yale Department of Internal MedicineYale New Haven HospitalNew HavenUSA
  2. 2.Department of DermatologyUniversity of Connecticut Health CenterFarmingtonUSA

Personalised recommendations